Human Cytomegalovirus as a Therapeutic Target in Glioma Stem Cells
Tarek Bou Dargham1,2, Eugene J Vaios2,3, Sean Lawler4
1Department of Neurosurgery, Duke University, Durham, NC 27710, USA.
Abstract:
Glioblastoma is the most aggressive tumor among gliomas, and recurrence remains inevitable despite aggressive therapies. Resistance to existing treatment modalities is attributed in part to the presence of glioma stem cells, which comprise a distinct cell subpopulation that sustains cell renewal and tumor evasion through multiple mechanisms. Therapeutic strategies using herpesviruses have been evaluated following the discovery of differential human cytomegalovirus (HCMV) expression in glioblastoma tumor cells. The absence of expression in normal brain tissue led to multiple clinical trials demonstrating the potential clinical utility of targeted HCMV via herpesvirus-based oncolytic therapeutic strategies. This review provides a comprehensive overview of existing studies evaluating the expression and biological significance of HCMV within glioma stem cells. Targeting HCMV in this cellular compartment may disrupt the continuous cellular support and resilience of glioblastoma stem cells, thereby enhancing the efficacy of current treatments.
Insights
Glioblastoma stem cells drive tumor recurrence. Targeting human cytomegalovirus (HCMV) within these cells offers a novel strategy to enhance glioblastoma treatment efficacy.
Area of Science:
- Neuro-oncology
- Virology
- Cancer Stem Cell Biology
Background:
- Glioblastoma is a highly aggressive brain tumor with frequent recurrence.
- Glioma stem cells (GSCs) contribute to treatment resistance and tumor evasion.
- Human cytomegalovirus (HCMV) is differentially expressed in glioblastoma.
Purpose of the Study:
- To review the expression and biological significance of HCMV in GSCs.
- To evaluate HCMV as a therapeutic target in glioblastoma.
Main Methods:
- Literature review of studies on HCMV expression in GSCs.
- Analysis of biological roles of HCMV in GSC maintenance and function.
- Assessment of herpesvirus-based oncolytic strategies targeting HCMV.
Main Results:
- HCMV is present and biologically significant within GSCs.
- Targeting HCMV may disrupt GSC support and resilience.
- HCMV-targeted therapies show potential clinical utility.
Conclusions:
- HCMV represents a promising therapeutic target within GSCs.
- Targeting HCMV could enhance the efficacy of current glioblastoma treatments.
- Further research into HCMV-GSC interactions is warranted.
More Related Videos
09:18Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018